FDA approval of a drug is a critical regulatory milestone that can significantly impact the parent company's stock price. For Eli Lilly, this approval not only enhances its product portfolio but also strengthens its position in the oncology segment. Given the importance of FDA approvals in the pharmaceutical industry, this news is likely to have a positive short-term impact on Eli Lilly's stock price.